http://www.xconomy.com/san-diego/2009/09/29/amylin-ceo-putting-boardroom-coup-behind-him-driven-to-nail-new-diabetes-drug/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/san-diego/2009/09/29/amylin-ceo-putting-boardroom-coup-behind-him-driven-to-nail-new-diabetes-drug/comment-page-1/#comment-84371 Luke Timmerman Thu, 01 Oct 2009 01:39:31 +0000 http://www.xconomy.com/?p=43550#comment-84371 Thanks for the comment, Carl. I've heard a few war stories about bureaucracy at Amylin, so your comments are pretty consistent with things I've heard from other former employees. If you or other employees have other insights you'd like to share, you can always e-mail me at ltimmerman@xconomy.com. It definitely helps being prepared when interviewing the execs--Luke Thanks for the comment, Carl. I’ve heard a few war stories about bureaucracy at Amylin, so your comments are pretty consistent with things I’ve heard from other former employees. If you or other employees have other insights you’d like to share, you can always e-mail me at ltimmerman@xconomy.com. It definitely helps being prepared when interviewing the execs–Luke

]]> http://www.xconomy.com/san-diego/2009/09/29/amylin-ceo-putting-boardroom-coup-behind-him-driven-to-nail-new-diabetes-drug/comment-page-1/#comment-84357 Carl Chessman Thu, 01 Oct 2009 00:19:10 +0000 http://www.xconomy.com/?p=43550#comment-84357 HAH! What a great spin on the same BS we've all heard before. Dan uses the very word: "execute", which is in fact why Amylin has failed to join the ranks of profitable biotechs. Thirty plus VPs, numerous buildings only half-full or empty, bad and untimely hiring decisions and a myriad of other bad examples too numerous to mention here. Amylin has great drugs, a great location, great benefits, and even some pretty smart people, but VERY poor execution. Disclosure: I'm a former Amylin employee with 24 years industry experience, so I had a frame of reference that's fairly realistic. For the sake of my fully-vested ESOP shares, I hope things work out, but if history is any lesson, they'll find a way to screw it up (they ALWAYS do). HAH! What a great spin on the same BS we’ve all heard before. Dan uses the very word: “execute”, which is in fact why Amylin has failed to join the ranks of profitable biotechs. Thirty plus VPs, numerous buildings only half-full or empty, bad and untimely hiring decisions and a myriad of other bad examples too numerous to mention here. Amylin has great drugs, a great location, great benefits, and even some pretty smart people, but VERY poor execution. Disclosure: I’m a former Amylin employee with 24 years industry experience, so I had a frame of reference that’s fairly realistic. For the sake of my fully-vested ESOP shares, I hope things work out, but if history is any lesson, they’ll find a way to screw it up (they ALWAYS do).

]]>